Hypermethylation within the TRAIL gene correlates with drug resistance in lung cancer [26], and the reversal of TRAIL methylation by methylation inhibitor treatment restores sensitivity to drug treatment [27–29]. This evidence concerns the gene TNFSF10 and lung carcinoma.